Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | DRD2 | P14416 | 1/20 | 0.67 |
| ▸ | DRD4 | P21917 | 1/20 | 0.67 |
| ▸ | HTR1B | P28222 | 2/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NSD2 | O96028 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HTR1D | P28221 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5715788 | 0.95 | KMT2A (0.63) | KMT2ADRD2DRD4HTR1BKCNH2 | |
| SCHEMBL7059928 | 0.95 | KMT2A (0.67) | KMT2ADRD2DRD4HTR1BKCNH2 | |
| Dimethylamine SCHEMBL3445328 | 0.83 | KMT2A (0.74) | KMT2ADRD2DRD4KCNH2KDM4E | |
| SCHEMBL9808215 | 0.81 | LMNA (0.67) | KMT2ADRD2DRD4KCNH2KDM4E | |
| SCHEMBL11455347 | 0.81 | DRD2 (0.64) | KMT2ADRD2DRD4KCNH2KDM4E | |
| SCHEMBL7237757 | 0.81 | HTR1B (0.65) | KMT2ADRD2DRD4HTR1BKDM4E | |
| SCHEMBL14308606 | 0.81 | DRD2 (0.69) | KMT2ADRD2DRD4HTR1BKDM4E | |
| SCHEMBL197632 | 0.80 | KMT2A (0.76) | KMT2ADRD2DRD4KCNH2KDM4E | |
| SCHEMBL10922507 | 0.80 | KMT2A (0.61) | KMT2ADRD2DRD4HTR1BKCNH2 | |
| SCHEMBL6846924 | 0.80 | DRD2 (0.68) | KMT2ADRD2DRD4KCNH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6756384-B2 | TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. | NOVO NORDISK A/S (DK) | 2004-06-29 | — | — | US | disclosed |
| US-20030135056-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2003-07-17 | — | — | US | disclosed |
| EP-1268484-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-6437147-B1 | FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM | NOVO NORDISK (DK) | 2002-08-20 | — | — | US | disclosed |
| US-20020058659-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2002-05-16 | — | — | US | disclosed |
| WO-2001068652-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135056-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | KMT2A 300/4885DRD2 668/4885DRD4 1390/4885 |
| US-20020058659-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | KMT2A 300/4885DRD2 668/4885DRD4 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.